ERYCAPS Technology Platform
ERYCAPS is ERYTECH’s proprietary platform to encapsulate active drug substances inside red blood cells using reversible hypotonic and hypertonic osmotic stress. Our ERYCAPS technology uses transfusion-grade red blood cells (RBCs) taken from blood donors with a specific blood type, compatible with the blood type of the patient to be treated. In order for therapeutic compounds to enter into the red blood cells, they are subjected to a hypotonic solution that causes swelling of the cells and opening of pores in the cellular membrane. At that time, therapeutic compounds can enter in the RBCs. Once the desired concentration of molecules is reached inside the RBCs, they are introduced to a hypertonic solution, causing the RBCs to take their original size and the pores to close, trapping the molecules inside the cell.
ERYCAPS is an innovative and versatile approach with significant benefits:
- Prolonged duration of activity: Red blood cells are biocompatible carriers that have a half-life of approximately one month in the body. This long half-life allows encapsulated therapeutic drug substances to remain in the body longer, thereby increasing the duration of their therapeutic activity and their potential efficacy with lower dosages and fewer injections.
- Decreased risk of side effects: The red blood cell membrane protects the body from toxicities associated with the encapsulated drug substance, reducing the potential for adverse side effects, such as allergic reactions.
- High reproducibility with rapid turnaround: The ERYCAPS encapsulation process is designed to produce batches of loaded red blood cells in a highly reproducible, reliable and rapid manner, regardless of the initial characteristics and origin of the red blood cells used. Delivery to the treating hospital can typically be performed within 24 hours of initiating production.
- Broad applicability: The ERYCAPS technology allows encapsulation of a broad range of molecules, from peptides to complex biological molecules within 1 and 500 kDalton in size, with broad applicability of therapeutic application. ERYTECH has focused the use of its platform on oncology, immuno-oncology, and enzymatic disorders.